Base de dados : MEDLINE
Pesquisa : D12.776.395.550.560 [Categoria DeCS]
Referências encontradas : 5587 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 559 ir para página                         

  1 / 5587 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29357376
[Au] Autor:Li Y; Zhou C; Li J; Liu J; Lin L; Li L; Cao D; Li Q; Wang Z
[Ad] Endereço:School of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Guangzhou, China.
[Ti] Título:Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells.
[So] Source:PLoS One;13(1):e0191024, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Muc1 is one of the most studied tumor antigens. However, antibodies or antibody-toxin conjugates against Muc1 have not shown significant efficacy for tumors with Muc1 overexpression. In this study, we employed bispecific antibody approach to target Muc1 positive tumor cells. A novel bispecific antibody, Muc1-Bi-1, was constructed by linking single domain antibodies, anti-Muc1-VHH and anti-CD16-VHH. Muc1-Bi-2, the humanized form of Muc1-Bi-1, was also constructed by grafting. Both Muc1-Bi bispecific antibodies can be efficiently expressed and purified from bacteria. In vitro, the Muc1-Bi bispecific antibodies can recruit Natural Killer (NK) cells to drive potent and specific cell killing of Muc1-overexpressing tumor cells. In xenograft model, the Muc1-Bi bispecific antibodies can suppress tumor growth in the presence of human peripheral blood mononuclear cells (PBMC). These data suggested that the single domain based Muc1-Bi may provide a valid strategy for targeting tumors with Muc1 overexpression.
[Mh] Termos MeSH primário: Anticorpos Biespecíficos/imunologia
Mucina-1/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Biespecíficos/genética
Células CHO
Linhagem Celular Tumoral
Proliferação Celular
Cricetulus
Ensaio de Imunoadsorção Enzimática
Citometria de Fluxo
Seres Humanos
Camundongos
Camundongos Endogâmicos NOD
Camundongos SCID
Neoplasias/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Bispecific); 0 (MUC1 protein, human); 0 (Mucin-1)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180123
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191024


  2 / 5587 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29297994
[Au] Autor:Karaulov AV; Gurina NN; Novikov DV; Fomina SG; Novikov VV
[Ti] Título:Role of MUC1 Expression in Tumor Progression.
[So] Source:Vestn Ross Akad Med Nauk;71(5):392-6, 2016.
[Is] ISSN:0869-6047
[Cp] País de publicação:Russia (Federation)
[La] Idioma:eng
[Ab] Resumo:Mucin 1 (MUC1) is a multistructural and multifunctional protein that is involved in regulating diverse cellular activities. This strongly glycosylated transmembrane protein forms a mucous gel on the surface of epithelial cells that protects the cells from injury. MUC1 acts as a signaling molecule and transcription factor modulating metabolism and resistance to bacterial-induced inflammation. This article presents a review of the relationship between structural and functional changes of the MUC1 and the characteristics of cancer cells. The alteration in MUC1 expression level, a number of structural forms, protein glycosylation and localization occurs in cancer cells. These alterations lead to metabolic reprogramming associated with proliferation, resistance to hypoxia and angiogenesis which affects the survival of cancer cells. Furthermore, cancer cells can take advantage of MUC1 interaction with adhesion molecules for invasion and metastasis. Thus, MUC1 plays a key role both in the homeostasis of epithelial cells and in cancer progression. Understanding the role of MUC1 expression in tumor cells survival is important for the development of new monitoring and therapeutic approaches for the treatment MUC1 positive maligancies.
[Mh] Termos MeSH primário: Mucina-1/metabolismo
Neoplasias
[Mh] Termos MeSH secundário: Progressão da Doença
Glicosilação
Seres Humanos
Neoplasias/metabolismo
Neoplasias/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (MUC1 protein, human); 0 (Mucin-1)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE
[do] DOI:10.15690/vramn736


  3 / 5587 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29324810
[Au] Autor:Spoorenberg SMC; Vestjens SMT; Voorn GP; van Moorsel CHM; Meek B; Zanen P; Rijkers GT; Bos WJW; Grutters JC; Ovidius study group
[Ad] Endereço:Department of Internal Medicine, St Antonius Hospital, Nieuwegein, The Netherlands.
[Ti] Título:Course of SP-D, YKL-40, CCL18 and CA 15-3 in adult patients hospitalised with community-acquired pneumonia and their association with disease severity and aetiology: A post-hoc analysis.
[So] Source:PLoS One;13(1):e0190575, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND AIM: SP-D, YKL-40, CCL18 and CA 15-3 are pulmonary markers that have been extensively investigated in different chronic pulmonary diseases. However, in acute pulmonary diseases, such as community-acquired pneumonia (CAP), little is known about the course of these markers and their relationship with the aetiological agent. The aim of this study was to investigate the course of these four markers in CAP and to study influence of disease severity, aetiology and antibiotic use prior to admission on their course. METHODS: We included 291 adult patients hospitalised with CAP and 20 healthy controls. Measurements were performed in serum of day 0, 2, and 4, and at least 30 days after admission. RESULTS: Our most important results were: 1) At all time-points, including 30 days after admission, YKL-40 and CCL18 levels were higher in CAP patients compared to healthy controls; and 2) Patients with CAP caused by an intracellular, atypical bacterium had lower YKL-40 and especially CCL18 levels on and during admission in comparison with other or unknown CAP aetiology. CONCLUSIONS: Our findings suggest that these pulmonary markers could be useful to assess CAP severity and, especially YKL-40 and CCL18 by helping predict CAP caused by atypical pathogens.
[Mh] Termos MeSH primário: Biomarcadores/sangue
Quimiocinas CC/sangue
Proteína 1 Semelhante à Quitinase-3/sangue
Infecções Comunitárias Adquiridas/sangue
Mucina-1/sangue
Pneumonia/sangue
Proteína D Associada a Surfactante Pulmonar/sangue
[Mh] Termos MeSH secundário: Infecções Comunitárias Adquiridas/etiologia
Infecções Comunitárias Adquiridas/fisiopatologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Pneumonia/etiologia
Pneumonia/fisiopatologia
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (CCL18 protein, human); 0 (CHI3L1 protein, human); 0 (Chemokines, CC); 0 (Chitinase-3-Like Protein 1); 0 (Mucin-1); 0 (Pulmonary Surfactant-Associated Protein D)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190575


  4 / 5587 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29193199
[Au] Autor:Liu C; Xie Y; Sun B; Geng F; Zhang F; Guo Q; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H
[Ad] Endereço:National Engineering Laboratory for AIDS Vaccine, College of Life Science, Jilin University, Changchun, China.
[Ti] Título:MUC1- and Survivin-based DNA Vaccine Combining Immunoadjuvants CpG and interleukin-2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model.
[So] Source:Scand J Immunol;87(2):63-72, 2018 Feb.
[Is] ISSN:1365-3083
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:DNA vaccination is a promising cancer treatment due to its safety, but poor immunogenicity limits its application. However, immunoadjuvants, heterogeneous prime-boost strategies and combination with conventional treatments can be used to improve the antitumour immune effects. A CpG motif and interleukin-2 (IL-2) cytokine are often used as adjuvants. In this study, a DNA vaccine containing a CpG motif was constructed to evaluate its adjuvant effect. The results show that the cytotoxicity of the DNA vaccine was increased fivefold, and survival lifetime was prolonged twofold by the CpG motif adjuvant. To simplify the industrial production process, a bicistronic plasmid was constructed to carry the fusion genes of survivin/MUC1 (MS) and IL-2 and with a CpG motif in its backbone. The results showed that the antitumour effect of the bicistronic vaccine was the same as that of the two vaccine co-injected regime. Furthermore, the vaccine could suppress metastatic tumour foci by 69.1% in colorectal carcinoma-bearing mice. Moreover, the vaccine induced survivin- and MUC1-specific immune responses in splenocytes and induced the immune promoting factor CCL-19 and GM-CSF upregulated, while metastatic-associated factor MMP-9 and immunosuppressing factor PD-L1 downregulated in tumour tissue. When combining the vaccine with the chemotherapy drug oxaliplatin, the survival was prolonged by about 2.5-fold. In conclusion, the DNA vaccine containing a CpG motif in bicistronic form showed good effects on colorectal cancer by inhibiting both tumour growth and metastasis, and combination with oxaliplatin could improve its antitumour effects.
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/genética
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Vacinas Anticâncer/imunologia
Neoplasias Colorretais/imunologia
Proteínas Inibidoras de Apoptose/genética
Mucina-1/genética
Oligodesoxirribonucleotídeos/genética
Compostos Organoplatínicos/uso terapêutico
Proteínas Repressoras/genética
Vacinas de DNA/imunologia
[Mh] Termos MeSH secundário: Animais
Vacinas Anticâncer/genética
Processos de Crescimento Celular
Linhagem Celular Tumoral
Neoplasias Colorretais/terapia
Modelos Animais de Doenças
Feminino
Genes/genética
Seres Humanos
Imunidade
Interleucina-2/administração & dosagem
Interleucina-2/imunologia
Camundongos
Camundongos Endogâmicos BALB C
Metástase Neoplásica
Plasmídeos
Vacinas de DNA/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Birc5 protein, mouse); 0 (CPG-oligonucleotide); 0 (Cancer Vaccines); 0 (Inhibitor of Apoptosis Proteins); 0 (Interleukin-2); 0 (Mucin-1); 0 (Oligodeoxyribonucleotides); 0 (Organoplatinum Compounds); 0 (Repressor Proteins); 0 (Vaccines, DNA); 0 (muc1 protein, mouse); 04ZR38536J (oxaliplatin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE
[do] DOI:10.1111/sji.12633


  5 / 5587 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457854
[Au] Autor:Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
[Ad] Endereço:Department of Etiology and tumor marker laboratory, Shanxi Cancer Hospital, Shanxi Province, China.
[Ti] Título:The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
[So] Source:Clin Chim Acta;470:51-55, 2017 Jul.
[Is] ISSN:1873-3492
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:This study aims to understand the diagnostic value of serum tumor markers carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), cancer antigen 125 (CA125), cancer antigen 15-3 (CA15-3), and tissue polypeptide-specific antigen (TPS) in metastatic breast cancer (MBC). A total of 164 metastatic breast cancer patients in Shanxi Cancer Hospital were recruited between February 2016 and July 2016. 200 breast cancer patients without metastasis in the same period were randomly selected as the control group. The general characteristics, immunohistochemical, and pathological results were investigated between the two groups, and tumor markers were determined. There were statistical differences in the concentration and the positive rates of CEA, CA19-9, CA125, CA15-3, and TPS between the MBC and control group (P<0.05). The highest sensitivity was in CEA and the highest specificity was in CA125 for the diagnosis of MBC when using a single tumor marker at 56.7% and 97.0%, respectively. In addition, two tumor markers were used for the diagnosis of MBC and the CEA and TPS combination had the highest diagnostic sensitivity with 78.7%, while the CA15-3 and CA125 combination had the highest specificity of 91.5%. Analysis of tumor markers of 164 MBC found that there were statistical differences in the positive rates of CEA and CA15-3 between bone metastases and other metastases (χ =6.00, P=0.014; χ =7.32, P=0.007, respectively). The sensitivity and specificity values of the CEA and CA15-3 combination in the diagnosis of bone metastases were 77.1% and 45.8%, respectively. The positive rate of TPS in the lung metastases group was lower than in other metastases (χ =8.06, P=0.005).There were significant differences in the positive rates of CA15-3 and TPS between liver metastases and other metastases (χ =15.42, P<0.001; χ =9.72, P=0.002, respectively). The sensitivity and specificity of the CA15-3 and TPS combination in the diagnosis of liver metastases were 92.3% and 45.6%, respectively, and the positive rate of CEA in triple-negative metastatic breast cancer is lower than in other subtypes (χ =4.80, P=0.028). Therefore, serum CEA, CA19-9, CA125, CA15-3, and TPS can be used in the diagnosis of MBC, and different combinations of tumor markers have varying diagnostic value.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/sangue
Neoplasias da Mama/sangue
Neoplasias da Mama/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Neoplasias da Mama/diagnóstico
Antígeno Ca-125/sangue
Antígeno CA-19-9/sangue
Antígeno Carcinoembrionário/sangue
Feminino
Seres Humanos
Meia-Idade
Mucina-1/sangue
Metástase Neoplásica
Peptídeos/sangue
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CA-125 Antigen); 0 (CA-19-9 Antigen); 0 (Carcinoembryonic Antigen); 0 (MUC1 protein, human); 0 (Mucin-1); 0 (Peptides); 0 (tissue polypeptide specific antigen)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  6 / 5587 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29277810
[Au] Autor:Svobodova S; Kucera R; Fiala O; Marie K; Narsanska A; Zedníková I; Treska V; Slouka D; Milena R; Topolcan O; Finek J
[Ad] Endereço:Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
[Ti] Título:CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer.
[So] Source:Anticancer Res;38(1):465-469, 2018 01.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:AIM: The aim of this study was to evaluate the ability of tissue polypeptide-specific antigen (TPS), carcinoembryonic antigen (CEA), and cancer antigen 15-3 (CA 15-3) to predict relapse in breast cancer patients, when the measurement of biomarkers is performed within 6 months after surgery. PATIENTS AND METHODS: Four hundred and seventy-two patients with breast cancer were evaluated. TPS, CEA, and CA 15-3 were measured in months 1, 3, and 6, after surgery. Disease recurrence was recorded between 7-12 months after surgery. Disease recurrence occurred in 60 patients, while 412 patients remained in recurrence-free status. RESULTS: TPS levels of the recurrence group differed statistically significantly in the first and sixth month after surgery compared to recurrence-free group (p=0.0339, AUC=0.6056; p<0.0001, AUC=0.7196). CEA and CA 15-3 measurements did not achieve a statistically significant difference for any month examined. CONCLUSION: TPS level in the sixth month after surgery is the best candidate biomarker to predict disease recurrence.
[Mh] Termos MeSH primário: Neoplasias da Mama/patologia
Neoplasias da Mama/cirurgia
Antígeno Carcinoembrionário/metabolismo
Mucina-1/metabolismo
Recidiva Local de Neoplasia/diagnóstico
Peptídeos/metabolismo
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores Tumorais
Feminino
Seres Humanos
Mastectomia Radical
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Carcinoembryonic Antigen); 0 (Mucin-1); 0 (Peptides); 0 (tissue polypeptide specific antigen)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE


  7 / 5587 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28745318
[Au] Autor:Ye J; Wei X; Shang Y; Pan Q; Yang M; Tian Y; He Y; Peng Z; Chen L; Chen W; Wang R
[Ad] Endereço:Department of Gastroenterology, Institute of Gastroenterology of PLA, Southwest Hospital, Third Military Medical University, Chongqing, China.
[Ti] Título:Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity.
[So] Source:Oncogene;36(46):6391-6407, 2017 Nov 16.
[Is] ISSN:1476-5594
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The attachment of cell-surface carbohydrates to proteins mediated by the amino acids serine or threonine (O-glycan) is involved in tumor metastasis; the roles of O-glycans vary depending on their structure, but the detailed mechanisms by which O-glycans trigger signaling to control tumor metastasis are largely unknown. In this study, we found that the reduced expression of core 3 synthase correlated with metastasis to lymph nodes and distant organs, resulting in poor prognosis for colorectal cancer (CRC) patients. Mechanically, we revealed that mucin-type core 3 O-glycan was synthesized at the membrane-tethered MUC1 N terminus because of core 3 synthase expression in colon cancer cells. This further inhibited the translocation of MUC1-C to the nucleus, initiated p53 gene transcription that was dependent on the inhibition of MUC1-C nucleus translocation, activated p53-mediated miR-200c expression and resulted in mesenchymal-epithelial transition (MET). Inhibition of MUC1 via small interfering RNA (siRNA) in re-expressed core 3 synthase colon cancer cells further inhibited MUC1-C nucleus translocation, increased p53 and miR-200c expression, and enhanced MET. However, inhibition of p53 via siRNA or miR-200c via miR-200c inhibitor in re-expressed core 3 synthase colon cancer cells promoted the epithelial-mesenchymal transition (EMT) in a reversible manner. Core 3 synthase mRNA levels and the p53 mRNA levels or miR-200c levels in the colon cancerous samples were positively correlated. Our findings suggest a novel mechanism linking mucin-type core 3 O-glycan to the EMT-MET plasticity of CRC cells via MUC1/p53/miR-200c-dependent signaling cascade and shed light on therapeutic strategies to treat this malignancy.
[Mh] Termos MeSH primário: Neoplasias Colorretais/genética
Transição Epitelial-Mesenquimal/genética
MicroRNAs/genética
Mucina-1/genética
Polissacarídeos/metabolismo
Proteína Supressora de Tumor p53/genética
[Mh] Termos MeSH secundário: Western Blotting
Células CACO-2
Linhagem Celular Tumoral
Núcleo Celular/metabolismo
Neoplasias Colorretais/metabolismo
Neoplasias Colorretais/patologia
Regulação Neoplásica da Expressão Gênica
Células HCT116
Células HT29
Seres Humanos
MicroRNAs/metabolismo
Mucina-1/metabolismo
Mucinas/metabolismo
N-Acetilglucosaminiltransferases/genética
N-Acetilglucosaminiltransferases/metabolismo
Transporte Proteico
Interferência de RNA
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Proteína Supressora de Tumor p53/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (MIRN200 microRNA, human); 0 (MUC1 protein, human); 0 (MicroRNAs); 0 (Mucin-1); 0 (Mucins); 0 (Polysaccharides); 0 (TP53 protein, human); 0 (Tumor Suppressor Protein p53); EC 2.4.1.- (N-Acetylglucosaminyltransferases); EC 2.4.1.- (UDP-GlcNAc GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171201
[Lr] Data última revisão:
171201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1038/onc.2017.241


  8 / 5587 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29034816
[Au] Autor:Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
[Ad] Endereço:1 Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
[Ti] Título:Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
[So] Source:Tumour Biol;39(10):1010428317730246, 2017 Oct.
[Is] ISSN:1423-0380
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Evidence is sparse regarding the clinical performance of luminescent oxygen channeling immunoassays-based tumor marker assays in gynecological cancer. Analyzing serum samples of 336 patients with Dimension™Vista1500, we investigated the diagnostic power of carbohydrate antigen 15-3, carbohydrate antigen 125, carcinoembryonic antigen, carbohydrate antigen 19-9, and alpha-fetoprotein in patients suffering from different types of gynecological cancer and precancerous gynecological diseases and compared findings to appropriate control groups. The cohort comprised 177 female patients with gynecological cancers (73 breast, 22 cervical, 16 endometrial, 17 vulva, and 49 ovarian cancers), 26 patients with precancerous gynecological diseases (11 vulva, 4 cervical, and 10 breast), 109 patients with benign gynecological diseases, and 24 healthy controls. Discriminative power was assessed by areas under the curve in receiver operating characteristic curves, and sensitivities were determined at a fixed specificity of 95%. Levels of biomarkers in healthy controls were in the expected ranges and a discriminative power between gynecological cancers and healthy controls was observed for several tumor markers. Established tumor type-associated markers were elevated in specific gynecological cancers and benign controls as well as within precancerous gynecological diseases and healthy control group. In ovarian cancer, carbohydrate antigen 125 and carbohydrate antigen 15-3 were significantly elevated compared to the respective benign diseases. Carbohydrate antigen 125 was the most conclusive marker (area under the curve = 0.86% and 77.6% sensitivity at 95% specificity). In breast cancer, carcinoembryonic antigen and carbohydrate antigen 15-3 were significantly higher than in the respective benign diseases. Carcinoembryonic antigen achieved the most conclusive area under the curve (0.65) with 31.5% sensitivity at 95% specificity. None of the investigated markers was found to be of value in discriminating benign and malignant cervical diseases. Carcinoembryonic antigen and alpha-fetoprotein distinguished precancerous breast and vulva diseases from healthy controls. These findings show that luminescent oxygen channeling immunoassays-based tumor marker assays provide reliable results in routine diagnostics.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/sangue
Antígeno Ca-125/sangue
Antígeno CA-19-9/sangue
Antígeno Carcinoembrionário/sangue
Neoplasias dos Genitais Femininos/sangue
Mucina-1/sangue
alfa-Fetoproteínas/metabolismo
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Antígenos de Neoplasias/sangue
Estudos de Casos e Controles
Feminino
Neoplasias dos Genitais Femininos/patologia
Seres Humanos
Imunoensaio/métodos
Meia-Idade
Curva ROC
Sensibilidade e Especificidade
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (Biomarkers, Tumor); 0 (CA-125 Antigen); 0 (CA-19-9 Antigen); 0 (Carcinoembryonic Antigen); 0 (Mucin-1); 0 (alpha-Fetoproteins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171017
[St] Status:MEDLINE
[do] DOI:10.1177/1010428317730246


  9 / 5587 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28982905
[Au] Autor:Yoshida K; Matsuyama R; Mori R; Kumamoto T; Matsuo K; Takeda K; Sugita M; Fujii Y; Tanaka K; Shimada H; Endo I
[Ad] Endereço:Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan kenichi@rd5.so-net.ne.jp.
[Ti] Título:Immunohistochemical Comparison of Malignancy Between Radial Invasion and Mucosal Extension in Hilar Cholangiocarcinoma.
[So] Source:Anticancer Res;37(10):5805-5812, 2017 10.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:AIM: To compare the cells of mucosal extension (ME) and radial invasion (RI) in hilar cholangiocarcinoma (HCCA) for optimal resection. MATERIALS AND METHODS: Forty-six patients underwent surgery for HCCA between 1992 and 2004. Immunohistochemical expressions of p53, Ki-67, matrix metalloproteinase-7 (MMP7), mucin 1 (MUC1), and E-cadherin were assessed at five different sites of the tumour and compared between the recurrence and non-recurrence groups. RESULTS: Expression of E-cadherin was significantly lower in RI cells than in ME cells, and that of MMP7 and MUC1 was significantly higher in RI cells than in ME cells. Ki-67 expression was higher in ME cells than in RI cells. During the 11-year follow-up, recurrence in patients with R0 resection was associated with significantly lower E-cadherin, higher MMP7, and higher Ki-67 expression. CONCLUSION: Removal of as many RI cells as possible should be a priority in resection of HCCA, followed by removal of ME cells. E-Cadherin appears to be associated with recurrence of HCCA.
[Mh] Termos MeSH primário: Neoplasias dos Ductos Biliares/química
Neoplasias dos Ductos Biliares/patologia
Biomarcadores Tumorais/análise
Imuno-Histoquímica
Tumor de Klatskin/química
Tumor de Klatskin/patologia
Membrana Mucosa/patologia
[Mh] Termos MeSH secundário: Idoso
Neoplasias dos Ductos Biliares/cirurgia
Caderinas/análise
Feminino
Seres Humanos
Antígeno Ki-67/análise
Tumor de Klatskin/cirurgia
Masculino
Metaloproteinase 7 da Matriz/análise
Meia-Idade
Mucina-1/análise
Invasividade Neoplásica
Recidiva Local de Neoplasia
Valor Preditivo dos Testes
Estudos Retrospectivos
Fatores de Risco
Fatores de Tempo
Resultado do Tratamento
Proteína Supressora de Tumor p53/análise
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CDH1 protein, human); 0 (Cadherins); 0 (Ki-67 Antigen); 0 (MUC1 protein, human); 0 (Mucin-1); 0 (TP53 protein, human); 0 (Tumor Suppressor Protein p53); EC 3.4.24.23 (MMP7 protein, human); EC 3.4.24.23 (Matrix Metalloproteinase 7)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE


  10 / 5587 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28949511
[Au] Autor:Xu C; Han X; Jiang Y; Yuan S; Wu Z; Wu Z; Qi X
[Ad] Endereço:Key Laboratory of Modern Chinese Medicines, China Pharmaceutical University , Nanjing 210009, PR China.
[Ti] Título:Microenvironmental Control of MUC1 Aptamer-Guided Acid-Labile Nanoconjugate within Injectable Microporous Hydrogels.
[So] Source:Bioconjug Chem;28(10):2530-2537, 2017 Oct 18.
[Is] ISSN:1520-4812
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Although aptamers are well-known as cell-specific membrane biomarkers for tumor-targeted therapy, it is important to avoid their degradation by nucleases in vivo. In this study, we developed a MUC1 aptamer-doxorubicin nanoconjugate (APT-DOX) through an acid-labile linkage and embedded APT-DOX into a thermosensitive hydrogel for antitumor therapy. The hydrogels exhibit a sol-gel transition upon intratumoral injection, resulting in the protection and controlled release control of APT-DOX with the shielding of the gel network. Moreover, the released APT-DOX was prone to be enriched at the tumor cells due to specific intracellular transport by the overexpressing MUC1 protein; however, APT-DOX regained the free DOX form via the rupture of the linkage under tumor cells lysosome acidic conditions and achieved increased concentration in the nucleus for antitumor treatment.
[Mh] Termos MeSH primário: Aptâmeros de Nucleotídeos/metabolismo
Portadores de Fármacos/química
Hidrogéis/química
Mucina-1/metabolismo
Nanoconjugados/química
Microambiente Tumoral
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/química
Antineoplásicos/metabolismo
Antineoplásicos/farmacologia
Transporte Biológico
Doxorrubicina/química
Doxorrubicina/metabolismo
Doxorrubicina/farmacologia
Liberação Controlada de Fármacos
Células Hep G2
Seres Humanos
Injeções
Células MCF-7
Camundongos
Porosidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Aptamers, Nucleotide); 0 (Drug Carriers); 0 (Hydrogels); 0 (Mucin-1); 0 (Nanoconjugates); 80168379AG (Doxorubicin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170927
[St] Status:MEDLINE
[do] DOI:10.1021/acs.bioconjchem.7b00324



página 1 de 559 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde